Get to know our clinical trials
Clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of VVD-130037.
EL OBJETIVO DE ESTA PARTE 2 DE AMPLIACIÓN DE LA DOSIS DEL ENSAYO CLÍNICO ES CONOCER LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE VVD-130037 EN SUJETOS CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) DE CÉLULAS ESCAMOSAS CON MUTACIONES NRF2 Y/O CUL3 QUE SE HA DISEMINADO A PESAR DE HABER RECIBIDO TODO EL ESTÁNDAR DE ATENCIÓN DISPONIBLE. VVD-130037 ES UN MEDICAMENTO EN INVESTIGACIÓN, LO QUE SIGNIFICA QUE NO ESTÁ APROBADO POR NINGUNA AUTORIDAD SANITARIA/COMPETENTE.
Technical Summary
- PHASE 1, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF VVD-130037, A KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) ACTIVATOR, IN PARTICIPANTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2023-506199-28-00
- Protocol number: VVD-130037-01
- Promoter: Vivideon Therapeutics
- Molecule/Drug: VVD-130037
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.